To our knowledge, this is the first report of multiple thrombo-embolic events in a patient with LE without peripheral eosinophilia. It provides new information on the natural history of this rare but clinically relevant disease.
Pathophysiology
In LE cardiac involvement with migration of eosinophils into the myocardium follows a stepwise pattern from subclinical acute necrosis of the myocardium [15], thrombosis as a result of damage to the endomyocardial surface and fibrosis [8, 16]. Typically, this leads to a restrictive or as in our patient dilated cardiomyopathy [17, 18].
Clinical presentation and diagnostic
Noninvasive multimodality imaging, including transthoracic- and transesophageal echocardiography as the mainstay of diagnostic imaging and surveillance for LE could, in our case, not provide classic findings as LV wall thickness, valvulopathy or LV thrombus [6, 10, 18]. Rather, the pattern of a dilated cardiomyopathy with LV enlargement and severely impaired LV function was detected [14]. Impaired tissue and organ function cause high morbidity and mortality [3]. Prognosis in LE therefore is poor due to high mortality from heart failure, sudden cardiac death or thrombo-embolism due to LV thrombus formation [12, 19, 20]. In a prospective study of 25 patients by Parrillo JE et al. [21], dyspnea was the most common symptom (42%), followed by chest pain (27%), heart failure (38%), cough (12%), palpitations (8%) and thrombo-embolic events (4%). Analysis of 26 case reports approved these findings, although thrombo-embolic events, predominantly presented as stroke related symptoms, was specified with a higher prevalence of 15% [11]. Among 33 cases of LE associated with LV thrombus, the incidence of an embolic stroke increased to 36.4% with a high mortality rate of 27.3% [8]. LV thrombus formation was found in 24% and right ventricular thrombus in 20%, documented in 55 patients with hypereosinophilic syndromes by a study from the Mayo clinic [22]. The evidence of a striking amount of spontaneous echo-contrast in transesophageal echocardiography resulting from low-velocity blood flow might, as discussed in the literature, be the underlying cause of thrombo-embolic events in our case, as LV thrombus formation was not detectable by echocardiography [18, 23]. It is also believed that eosinophils may contribute to thrombus formation by binding to thrombomodulin and impairing the inherent anticoagulant properties of the endothelial membrane [24]. CMR imaging is a powerful noninvasive modality in providing diagnostic and follow-up information in these patients, in particular if suspicious for the diagnosis of LE with thrombus formation, however, not possible in our case [12, 18]. EMB remains the gold standard, confirming the diagnosis also in our case, although containing risks, such as sampling errors or iatrogenic embolism [18, 25].
Medical therapy
A beneficial effect of immunosuppressive therapy with prednisone and azathioprine with significant improvement of LV function and decrease of LV dimensions was first shown in a randomized placebo-controlled study by Frustaci et al. in 2009 [26]. In the study by Brambatti et al., however, 78% of patients with eosinophilic myocarditis received corticosteroids and a minority had an additional immunosuppressant, however, uncertainty remained to what degree immunosuppression affected outcome [14]. The treatment of LE in particular, is mainly based on case reports and small case series and guidelines or consensus statements for the treatment of eosinophilic myocarditis/LE are still missing [27]. Aiming the optimal therapeutic strategy for our patient, immunosuppressive therapy was started after confirming the diagnosis by EMB. Considering LE patients with an intracardiac thrombus formation in a review including 32 studies, steroids were administered in 81.8% of patients, achieving a rapid decrease in the eosinophil count [12]. As no peripheral eosinophilia was present in our case, this therapeutic effect was not measurable.
The goal of recommended medical therapy in LE, including heart failure management and anticoagulation if presence of an intracardiac thrombus, is a decrease of eosinophil-mediated end-organ damage and prevent adverse thrombotic events [11, 12, 16, 28]. In our patient, presenting with clinical signs of acute heart failure and severely reduced LV function, medical heart failure therapy was started immediately, but was limited to a ß-blocker due to the need of renal replacement. In addition, our patient was put on continuous therapeutic anticoagulation promptly after presenting with systemic thrombo-embolic events and a striking amount of spontaneous echo-contrast in echocardiographic imaging. In analogue with the high amount of 69.7% of patients treated with anticoagulant therapy with a detectable decrease in thrombus mass [12], the amount of detectable spontaneous echo contrast decreased in echocardiographic follow-up study in our patient, although LV systolic function remained severely impaired. The role of anticoagulation, however, in patients with spontaneous echo-contrast and to prevent endocavitary thrombus formation is unclear and might be of high interest in patients with LE.
Risk assessment
Decision for premature implantable cardioverter defibrillator system remain challenging in patients with impaired LV function (ejection fraction ≤ 35%), but should be avoided in patients with inflammatory cardiomyopathy as LV function may improve significantly with guideline-based heart failure therapy [4]. Close surveillance is necessary in patients like ours.